AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00135330 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: exenatide
Description: subcutaneous injection, 5mcg or 10mcg, twice a day
Study NCT00135330 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rosiglitazone
Description: oral tablet, 2mg or 4mg, twice a day
Study NCT04380909 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet-based self-help
Description: Six cognitive-behavioral, mindfulness and acceptance commitment based modules focusing on different aspects of psychological distress due to the Covid-19 situation.
Study NCT04380909 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Internet-based self-help after 3 weeks
Description: Six cognitive-behavioral, mindfulness and acceptance commitment based modules focusing on different aspects of psychological distress due to the Covid-19 situation.
Study NCT04920071 — intervention group
Intervention type: DEVICE
Intervention: Visual acuity and contrast sensitivity measurement
Description: Those subjects who meet the inclusion criteria will undergo the study tests. These measurements will be performed on one eye only. Visual acuity will be quantified using two forms of the MAC chart (MAC 1 and 2) and two forms of a conventional letter design chart (C1 and 2). Contrast sensitivity will be measured using the two forms of the Pelli-Robson chart (CS1 and CS2). The order with which the test charts will be presented, in addition to the charts used (i.e. MAC 1 or 2, C1 or 2, and CS1 or 2), will be selected at random. Finally, a measurement of eye length will be collected using an IOL Master (Carl-Zeiss Meditec, USA).
Study NCT03068936 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Cisplatin
Description: Synchronous cisplatin (100mg / m2 / times) chemotherapy, once every 3 weeks, a total of 2 times
Study NCT03807778 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mobocertinib
Description: Mobocertinib capsule.
Study NCT02212366 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active TDCS
Description: Active Stimulation
Study NCT01983878 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramucirumab
Description: Administered IV
Study NCT00241449 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: intramuscular injection 250 mg
Study NCT00241449 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tamoxifen
Description: 20 mg oral tablet
Study NCT02109744 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Study NCT02212366 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham TDCS
Description: Sham Stimulation
Study NCT02082444 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Skipping lunch
Study NCT02048358 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2B3-201
Study NCT03879928 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Single ascending doses of FM101
Description: The study drug (FM101 and placebo comparator) will be administered orally as SAD doses
Study NCT02048358 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study NCT03879928 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Single ascending doses of FM101
Description: The study drug (FM101 and placebo comparator) will be administered orally as SAD doses
Study NCT03879928 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Multiple ascending doses of FM101
Description: The study drug (FM101 and placebo comparator) will be administered orally as MAD doses
Study NCT03879928 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Multiple ascending doses of FM101
Description: The study drug (FM101 and placebo comparator) will be administered orally as MAD doses
Study NCT03879928 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Food effects of FM101
Description: The study drug (FM101) will be administered orally under fasted condition and fed condition.
Study NCT04434547 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PRP
Description: During the mock embryo transfer on oocyte retrieval day, 1ml of PRP was infused inside the uterus
Study NCT02933879 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NVXT topical
Description: topical treatment
Study NCT02933879 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (Vehicle) Topical
Description: Placebo (Vehicle) Topical
Study NCT03371576 — intervention group
Intervention type: DEVICE
Intervention: intraocular lenses
Study NCT02048358 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone hemisuccinate
Study NCT02969967 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SaeboFlex
Description: Use of the SaeboFlex orthosis for a set protocol of grasp-release activities for 50 minutes at least 3 times per week, followed by 10 minutes of grasp-release activities without the orthosis for 8 weeks. Will occur in participants' homes after discharge from inpatient rehabilitation with visit from principal investigator to progress program for 1 hour 3 times a week for the first 2 weeks and then once a week for 6 weeks.
Study NCT04122586 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tongxieyaofang(granule)
Description: Take this granule twice a day,one bag for each time,one hour after a meal,for 4 weeks
Study NCT02566616 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ulnar Nerve Stimulation
Description: 1 hour of continued stimulation of the ulnar nerve using a hand held stimulator
Study NCT02566616 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ulnar Nerve Stimulation
Description: 1 hour of continued stimulation of the ulnar nerve using a hand held stimulator
Study NCT03490019 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: 500, 850 or 1000 mg depending on body weight once daily for 24 weeks
Study NCT03747536 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipratropium bromide
Description: ipratropium bromide via metered dose spray (21 micrograms per spray)
Study NCT03747536 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: normal saline delivered via metered dose spray
Study NCT02529670 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laser
Description: Low level laser therapy will be delivered through Laser Photon III ® (DMC) in the second lumbar dorsal root ganglion.
Study NCT02529670 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Drug: Lidocaine
Description: 1 mL of Lidocaine will be delivered in the second lumbar dorsal root ganglion through fluoroscopy.
Study NCT02529670 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Radiofrequency
Description: Radiofrequency will be delivered during 300 seconds, 42oC in the second lumbar dorsal root ganglion.
Study NCT00297128 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: 825 mg/m2 bid (on each therapy day of first 4 therapy weeks)
Study NCT00297128 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cetuximab
Description: 400mg/m2 week 1, 250mg/m2 week 2-4
Study NCT01391338 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP3652
Description: Oral
Study NCT01391338 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral
Study NCT00791804 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AeroLEF
Description: Inhaled AeroLEF (Liposome-Encapsulated Fentanyl 500 mcg/mL)~* for nebulized administration as required by the patient.~* Up to a 6 mL volume (2 x 3 mL doses) containing 500 mcg/ml fentanyl.
Study NCT01160861 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEMP1972A
Description: Repeating ascending dose
Study NCT01160861 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Repeating ascending dose
Study NCT01531361 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crizotinib
Description: Given PO
Study NCT01531361 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT01531361 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study NCT01531361 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib Tosylate
Description: Given PO
Study NCT01531361 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vemurafenib
Description: Given PO
Study NCT01027572 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Implantable neurostimulation system (Medtronic)
Description: Thalamic stimulation will be performed using an implantable neurostimulation system
Study NCT04411706 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab Combined With Apatinib and Capecitabine
Description: Drug: Sintilimab 200mg (3mg/kg for underweight patients) intravenously, every 21 days for a cycle;~Drug: Apatinib,250mg po qd, for continuous medication;~Drug: Capecitabine,1000mg/m2 po bid, d1-d14, every 21 days for a cycle;
Study NCT02644252 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Day 1: Cisplatin 75 mg/m2
Study NCT02644252 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Day 1: Vinorelbine 25 mg/m2
Study NCT02644252 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Day 8: Capsule vinorelbine 50 mg/m2
Study NCT03337165 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: tolerogenic dendritic cells
Description: dose-escalation
Study NCT03852173 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Wasserschulen
Description: Schools receive following materials and trainings:~* one training sessions for teachers (at the beginning of the intervention)~* refillable water bottles for each school student~* drying rack for water bottles for each classroom~* educational material for each class and for school events~* informational material for parents
Study NCT01831765 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Faster-acting insulin aspart
Description: Injected subcutaneously (s.c., under the skin), dose individually adjusted. Meal time dosing is defined as injecting 0-2 minutes before the meal.
Study NCT01831765 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin detemir
Description: Injected subcutaneously (s.c., under the skin), dose individually adjusted. Administrated once or twice daily.
Study NCT01831765 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin detemir
Description: Injected subcutaneously (s.c., under the skin), dose individually adjusted. Administrated once or twice daily.
Study NCT01831765 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin aspart
Description: Injected subcutaneously (s.c., under the skin), dose individually adjusted.
Study NCT01831765 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Faster-acting insulin aspart
Description: Injected subcutaneously (s.c., under the skin), dose individually adjusted. Post meal time dosing is defined as injecting 20 minutes after the start of the meal.
Study NCT03322618 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: blood samples
Description: 7 tubes of 6 ml (42 ml of blood )
Study NCT03322618 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: blood samples
Description: 7 tubes of 6 ml (42 ml of blood )
Study NCT02149290 — intervention group
Intervention type: DEVICE
Intervention: Trends-equipped LifeVest 4000
Description: LifeVest 4000 monitors patients for VT/VF, notifies the patient if VT/VF occurs, and instructs them to press response buttons. In unresponsive patients, LifeVest delivers defibrillation therapy. Trends modifications for heart failure monitoring include: body position data collection; heart rate measurements, activity data collection; ability to perform a health survey; ability to guide patients through a walk test
Study NCT02314091 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: onlay mesh hernioplasty
Study NCT00899990 — intervention group
Intervention type: OTHER
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02299271 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: 0.375% ropivacaine as a one-time, 60 milliliter injection
Study NCT02299271 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Saline as a one-time, 60 milliliter injection.
Study NCT00768157 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: radical resection of HBV-related HCC
Description: Procedure/Surgery - radical resection of HBV-related HCC
Study NCT00768157 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: radical resection of HBV-related HCC
Description: Procedure/Surgery - radical resection of HBV-related HCC
Study NCT03426813 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Historical control group for early mobilization
Study NCT01335191 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TUTI-16 (1.0 mg)
Description: Two subcutaneous injections of TUTI-16 (1.0 mg) at Day 0 and Week 3.
Study NCT01482468 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: continuous infusion of palonosetron added to prophylactic single injection of palonosetron
Description: continuous infusion of palonosetron 0.00075 mg/hour after single injection of palonosetron 0.075mg
Study NCT01482468 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: continuous infusion of normal saline added to prophylactic single injection of palonosetron
Description: continuous infusion of normal saline after single injection of palonosetron 0.075mg
Study NCT01478061 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Anastomosis (C-Port® )
Description: creation of anastomoses in blood vessels and grafts, including use in coronary artery bypass grafting procedures
Study NCT03563261 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Collagen supplement group
Description: Participants from both group will take their supplement every morning prior to breakfast. Supplementation period will be 4 months. They will perform tendons loading activities 30 minutes after ingestion of the supplement. Tendons loading activities will be heel raises and knee extensions while seated. Participants will be asked to keep the exercise intensity low as it is not a strengthening intervention.
Study NCT03563261 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo supplement group
Description: Participants from both group will take their supplement every morning prior to breakfast. Supplementation period will be 4 months. They will perform tendons loading activities 30 minutes after ingestion of the supplement. Tendons loading activities will be heel raises and knee extensions while seated. Participants will be asked to keep the exercise intensity low as it is not a strengthening intervention.
Study NCT01728727 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: UC-MSC transplantation
Description: After enrolled, Participant will receive umbilical cord MSC transplantation of 1\*10E6 cells/kg via hepatic artery. Participant will then be followed until 1 years study visit
Study NCT01728727 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: conventional treatment
Description: Participants will receive conventional treatment and antiviral treatment.
Study NCT03261570 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pyridostigmine
Description: 60mg by mouth
Study NCT03261570 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Digoxin
Description: 0.5 (500mcg) by mouth
Study NCT03261570 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Lactulose 50mg by mouth
Study NCT01261260 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Uridine
Description: 1 gram tablets BID for 7 days
Study NCT01052831 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naltrexone
Description: 50-100 mg qd for 8 weeks
Study NCT01052831 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 50-100 mg qd for 8 weeks
Study NCT01191281 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diet/nutrition counsel+food aid
Description: Patients enrolled in the experimental arm will receive dietary and nutritional assistance plus a food aid basket, specifically tailored to meet the nutritional needs of the target population.
Study NCT01191281 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dietary/nutrition counsel
Description: Patients enrolled in the active comparison arm will receive dietary and nutrition counseling designed to help them meet their nutrition needs, based on foods which are locally available, culturally acceptable and within their budget.
Study NCT03790540 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DentalVibe
Description: It is a vibrotactile device that aids in reducing pain during local anesthesia injection in pediatric patients
Study NCT03790540 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topical Benzocaine 20%
Description: Topical benzocaine 20% gel on the mucosal injection site prior to injection
Study NCT05070325 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cold application group
Description: Cold application group (Group 1): In the children in this group, the injection site was cleaned before the injection using antiseptic cotton and then the gel pad was placed on the injection site. In line with the literature, the cold gel pad was applied to the intramuscular injection site for 30-45 seconds before the injection and then the injection was delivered. The children were told to breathe deeply and not to tense up during the injection.
Study NCT05070325 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Shotblocker group
Description: Shotblocker group (Group 2): The injection site was cleaned using antiseptic cotton. The surface of the Shotblocker with the contact points was placed on the site just before the injection in a way not to contaminate the injection point. Injection was carried out through the opening in the middle of ShotBlocker. The children were told to breathe deeply and not to tense up during the injection. After the injection was completed, ShotBlocker was removed from the skin.
Study NCT05070325 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control Group
Description: Control Group (Group 3): The routine IM injection was applied to the children in this group. The injection site was cleaned using antiseptic cotton. The children were told to breathe deeply and not to tense up during the injection.
Study NCT00838383 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sitaxsentan (Thelin)
Description: sitaxsentan (1.0 mg/kg) will begin immediately following cross-clamp release and 12 hours post-CPB.
Study NCT00838383 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sitaxsentan (Thelin)
Description: Sitaxsentan (2.0 mg/kg) will begin immediately following cross-clamp release and 12 hours post-CPB.
Study NCT00838383 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will begin immediately following cross-clamp release and 12 hours post-CPB.
Study NCT04266158 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Myoelectric UE Device-UE Orthosis-No Device
Description: all subjects receive 2 education sessions, during which they are trained on the donning and use of the MyoPro 2 Motion-G, orthosis, and no device, all on the affected UE. The presentation and training on these interventions is non-randomized and administered to all subjects.
Study NCT03678818 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medium Supplemented with Latrunculin A
Description: A medium with in-house supplementation of Latrunculin A to decrease oocyte degeneration after ICSI and improve the survival rate
Study NCT01564602 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: comparison multiple channel port laparoscopic surgery
Description: to compare 2-channel single port and multiple channel port laparoscopic surgery
Study NCT02254551 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LDE225
Description: Lead-In: LDE225 will be administered orally at three dose levels starting at 400mg. If acceptable tolerability is demonstrated, escalations may continue up to 800 mg. LDE225 will be administered orally as a single daily dose for 21 days in combination with a fixed dose of bortezomib to be given on Days 1, 4, 8, 11 of each 21 day cycle.~Dose Expansion: LDE225 will be given as a single oral daily dose for 21 days at the MTD determined in the lead-in phase.~Maintenance Therapy: Patients who complete 16 cycles of therapy with stable disease or better will be eligible for single agent maintenance therapy of LDE225 at the MTD orally for up to 2 years or until progressive disease or unacceptable toxicity.
Study NCT02254551 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: In both the lead-in and dose expansion portions of the study, bortezomib, 1.3 mg/m2, will be administered by subcutaneous injection (SQ) on Days 1, 4, 8, 11 of each 21 day cycle.